Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1192446 | 0.96 | EGLN1 (0.92) | EGLN1 | |
| SCHEMBL1192823 | 0.89 | EGLN1 (0.93) | EGLN1 | |
| SCHEMBL3033393 | 0.87 | EGLN1 (0.78) | EGLN1 | |
| SCHEMBL1193132 | 0.87 | EGLN1 (0.93) | EGLN1 | |
| SCHEMBL1192820 | 0.86 | EGLN1 (0.93) | EGLN1 | |
| SCHEMBL12876444 | 0.86 | EGLN1 (0.75) | EGLN1 | |
| SCHEMBL1193190 | 0.85 | EGLN1 (1.00) | EGLN1 | |
| SCHEMBL1193009 | 0.85 | EGLN1 (1.00) | EGLN1 | |
| SCHEMBL13261530 | 0.85 | EGLN1 (0.75) | EGLN1 | |
| SCHEMBL1193516 | 0.85 | EGLN1 (0.93) | EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369678-A1 | BENZIMIDAZOLE DERIVATIVE FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-02 | — | — | US | disclosed |
| CN-113382729-A | Benzimidazole derivatives for the treatment of inflammatory disorders | 阿克比治疗有限公司 | 2021-09-10 | — | — | CN | disclosed |
| WO-2020072645-A1 | BENZIMIDAZOLE DERIVATIVE FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS | AKEBIA THERAPEUTICS, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369678-A1 | BENZIMIDAZOLE DERIVATIVE FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS | SI, CYP2E1, ALPI | EGLN1 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.